the treatment, successfully tested at the university of virginia’s school of medicine, is now authorized to treat dyskinesias, the involuntary movements and mobility issues commonly associated with the disease. the device, known as the insightec exablate neuro , uses focused ultrasound — instead of drugs or invasive surgery — to interrupt the faulty brain circuits underlying such symptoms.
“this fda approval of focused ultrasound pallidotomy allows for more treatment options if medications become ineffective or cause disabling side effects,” said jeff elias , a health surgeon and pioneer in the field of focused ultrasound who led the testing of the technology at uva.
advertisement
parkinson’s disease is a brain disorder that occurs when clusters of nerve cells (or neurons) controlling the body’s movement die or malfunction, resulting in a decrease in the production of dopamine. doctors are unsure exactly what causes these cells to die, but their destruction leads to motor control issues that can have a debilitating effect on patients.
there are more than 100,000 canadians living with parkinson’s today and roughly 6,600 new diagnoses every year, most occurring around the age of 65 when symptoms become undeniable. it costs more than $1.2-billion annually in canada to manage the symptoms and associated costs of the disease, with some medications costing the typical patient more than $1,000 per month.
advertisement
dave yasvinski is a writer with healthing.ca